On July 9, 2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, reported that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, July 13 at 5:00 p.m. ET (Press release, SAB Biotherapeutics, JUL 9, 2021, View Source [SID1234584761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ:BCYP). The transaction is expected to close in the fourth quarter of 2021.